Will Apogee Therapeutics’ APEX data shift competitive dynamics against Dupixent and Ebglyss?
Apogee Therapeutics prepares to release 52-week APEX data for zumilokibart. Discover what it could mean for eczema treatment and competition.
Pharma & Biotech
Pharma & Biotech
AbbVie’s AFFIRM trial: what clinicians should watch next for risankizumab in Crohn’s disease
AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.
Pharma & Biotech
Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
Pharma & Biotech
How Leyden’s CR9114 nasal spray could disrupt traditional flu vaccination models
Could a nasal spray replace flu shots? Find out how Leyden Labs’ CR9114 antibody is changing the game in influenza prevention.
Pharma & Biotech
Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development
Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.
Pharma & Biotech
Veloxis Pharmaceuticals’ pegrizeprument gets orphan status—will FDA incentives accelerate clinical momentum?
Veloxis earns FDA orphan status for pegrizeprument in liver transplant rejection. Find out what this means for the future of immunosuppressive therapy.
Medical Devices & Diagnostics
BioStem acquires Neox and Clarix as BioTissue refocuses on eye care therapies
BioTissue exits surgical wound care to refocus on eye care innovation, selling Neox and Clarix lines to BioStem. Find out what this deal changes in MedTech.
Pharma & Biotech
INTENT Biologics secures FDA pediatric waiver, clears path to late-stage DFU trial for PEP Biologic
The U.S. Food and Drug Administration (FDA) has granted INTENT Biologics a full pediatric study waiver for its lead candidate, PEP Biologic, under IND 019567. The waiver, part of an agreed Initial Pediatric Study Plan (iPSP), applies to the product’s adult-focused development for diabetic foot ulcers (DFUs), a serious chronic wound indication preparing for pivotal
Pharma & Biotech
Can GSK’s $2.2bn acquisition of RAPT Therapeutics reshape the food allergy treatment landscape with ozureprubart?
GSK plc has signed a definitive agreement to acquire RAPT Therapeutics Inc., a clinical-stage biopharmaceutical company based in California, in a transaction valued at approximately $2.2 billion. The centerpiece of the deal is ozureprubart, a long-acting anti-IgE monoclonal antibody currently undergoing Phase IIb evaluation for the prophylactic treatment of food allergies. With topline data from
Pharma & Biotech
Akeso’s gumokimab advances to NMPA review in ankylosing spondylitis: Is China’s IL-17 race entering a new phase?
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after Phase 3 success. Find out what this could mean for IL-17 therapies in China.